RB1 and cancer: It has been reported that Rb1 and its metabolite compound K can effectively suppress cancer stem cell self-renewal without regrowth, and Rb1 and compound K treatment also sensitized cancer stem cells to clinically relevant doses of cisplatin and paclitaxel 64.